No.38 文献リスト [GPCR PathHunter Arrestin]-3

DiscoveRxのPathHunter アレスチンアッセイは、高い信頼性を誇るGPCR機能アッセイでございます。現在150報以上に及ぶ文献が報告されており、世界中の研究者の皆様にご活用いただいています。5回に分けて本ブログに掲載させていただいております。（※ターゲット毎に分類されております。）

文献リスト [GPCR PathHunter Arrestin]-1
文献リスト [GPCR PathHunter Arrestin]-2

Class A Orphan Receptors (クラスAオーファン受容体)

GPCR Target	Reference
Orphans	Southern C, Cook JM, Neetoo-Isseljee Z, Taylor DL, Kettleborough CA, Merritt A, Bassoni DL, Raab WJ, Quinn E, Wehrman TS, Davenport AP, Brown AJ, Green A, Wigglesworth MJ and Rees S. (2013). Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen 18(5):599-609.
GPR3	Ye C, Zhang Z, Wang Z, Hua Q, Zhang R, Xie X.. (2014).Identification of a novel small-molecule agonist for human G protein-coupled receptor 3. J Pharmacol Exp Ther. 349(3):437-43.
GPR18	Console-Bram L, Brailoiu E, Brailoiu GC, Sharir H, Abood ME. (2014). Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br J Pharmacol. 171(16):3908-17.
GPR18, GPR55	Rempel V, Atzler K, Behrenswerth A, Karcz T, Schoeder C, Hinz S, Kaleta M, Thimm D, Kiec-Kononowiczb K, Muller CE (2014). Bicyclic imidazole-4-one derivatives: a new class of antagonists for the orphan G protein-coupled receptors GPR18 and GPR55. MedChemComm 5, 632-49.
GPR18, GPR55	Fuchs A, Rempel V and Muller CE. (2013). The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonists. PLoS One 8(10): e77739.
GPR32	Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G and Serhan CN. (2012). Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol 180(5):2018-27.
GPR32	Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA and Serhan CN. (2010). Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci USA 107(4):1660-5.
GPR35	MacKenzie AE, Caltabiano G, Kent TC, Jenkins L, McCallum JE, Hudson BD, Nicklin SA, Fawcett L, Lane R, Charlton SJ and Milligan G. (2014). The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol Pharmacol 85(1):91-104.
GPR35	Neetoo-Isseljee Z, MacKenzie AE, Southern C, Jerman J, McIver EC, Harries N, Taylor DL and Milligan G. (2013). High-throughput identification and characterization of novel, species-selective GPR35 agonists. J Pharmacol 344(3): 568-78.
GPR35	Jenkins L, Alvarez-Curto E, Campbell K, de Munnik S, Canals M, Schlyer S and Milligan G. (2011). Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Galpha(1)(3) and beta-arrestin-2. Br J Pharmacol 162(3):733-48.
GPR35, GPR55	Reggio P, Shore D. (2015). The Therapeutic Potential of Orphan GPCRs, GPR35 and GPR55. Front Pharmacol (review article) 6:69.
GPR35, GPR55	Funke M, Thimm D, Schiedel AC and Muller CE. (2013). 8-benzamidochromen-4-one-2-carboxylic acids - potent and selective agonists for the orphan G protein-coupled receptor GPR35. J Med Chem 56(12):5182-97.
GPR55	Kargl J, Brown AJ, Andersen L, Dorn G, Schicho R, Waldhoer M and Heinemann A. (2013). A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther 346(1):54-66.
GPR55	Rempel V, Volz N, Gluser F, Nieger M, Bruse S and Muller CE. (2013). Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. J Med Chem56(11):4798-810.
GPR55	Yamashita A, Oka S, Tanikawa T, Hayashi Y, Nemoto-Sasaki Y, Sugiura T. (2013). The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55. Prostaglandins Other Lipid Mediat 107:103-16.
GPR101	Cho-Clark M, Larco DO, Semsarzadeh NN, Vasta F, Mani SK, Wu TJ. (2014). GnRH-(1-5) Transactivates EGFR in Ishikawa Human Endometrial Cells via an Orphan G Protein-Coupled Receptor. Mol Endocrinol 28(1):80-98.
Orphan Panel, GPR173	Larco DO, Cho-Clark M, Mani SK and Wu TJ. (2013). The metabolite GnRH-(1-5) inhibits the migration of immortalized GnRH neurons. Endocrinology 154(2):783-95.
EBI2 (GPR183)	Gessier F, Preuss I, Yin H, Rosenkilde MM, Laurent S, Endres R, Chen YA, Marsilje TH, Seuwen K, Nguyen DG, Sailer AW (2014). Identification and characterization of small molecule modulators of the Epstein-Barr virus-induced gene 2 (EBI2) receptor. J Med Chem. 57(8):3358-68.
EBI2 (GPR183)	Benned-Jensen T, Norn C, Laurent S, Madsen CM, Larsen HM, Arfelt KN, Wolf RM, Frimurer T, Sailer AW, Rosenkilde MM. (2013). Molecular characterization of oxysterol binding to the Epstein-Barr virus-induced gene 2 (GPR183). J Biol Chem 287(42):35470-83.
EBI2 (GPR183)	Benned-Jensen T, Madsen CM, Arfelt KN, Smethurts C, Blanchard A, Jepras R, Rosenkilde MM. (2013). Small molecule antagonism of oxysterol-induced Epstein-Barr virus induced gene 2 (EBI2) activation. FEBS Open Bio. 19;3:156-60.

Dopamine Receptors (ドーパミン受容体)

GPCR Target	Reference
DRD1	Conroy JL, Free RB, Sibley DR. (2015) Identification of G Protein-Biased Agonists That Fail To Recruit β-Arrestin or Promote Internalization of the D1 Dopamine Receptor. ACS Chem Neurosci.
DRD1	Lee SM, Kant A, Blake D, Murthy V, Boyd K, Wyrick SJ, Mailman RB. (2014) SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C. Neuropharmacology. 86:145-54
DRD2	Brust TF, Hayes MP, Roman DL, Burris KD, Watts VJ.(2015) Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways. J Pharmacol Exp Ther.352(3):480-93
DRD2	Dix AV, Conroy JL, George Rosenker KM, Sibley DR, Appella DH.(2015) PNA-Based Multivalent Scaffolds Activate the Dopamine D2 Receptor. ACS Med. Chem. Lett
DRD2	Free RB, Chun LS, Moritz AE, Miller BN, Doyle TB, Conroy JL, Padron A, Meade JA, Xiao J, Hu X, Dulcey AE, Han Y, Duan L, Titus S, Bryant-Genevier M, Barnaeva E, Ferrer M, Javitch JA, Beuming T, Shi L, Southall NT, Marugan JJ, Sibley DR (2014). Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor. Mol Pharmacol. 2014 86(1):96-105.
DRD2	Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Yadav PN, Huang XP, Feng B, Jensen NH, Che X, Bai X, Frye SV, Wetsel WC, Caron MG, Javitch JA, Roth BL, Jin J. (2011). Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci USA 108(45):18488-93.
DRD2, DRD3	van Wieringen JP, Michel MC, Janssen HM, Janssen AG, Elsinga PH, Booij J. (2014). Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors. EJNMMI Research 4:53
DRD2, DRD3	Xiao J, Free RB, Barnaeva E, Conroy J, Doyle T, Bryant-Genevier M, Taylor MK, Southall N, Hu X, Ferrer M, Titus S, Zheng W, Sibley DR, Marugan JJ. (2014). Discovery, optimization, and characterization of a novel series of dopamine D2 versus D3 receptor selective antagonists. Probe Reports from the NIH Molecular Libraries Program [Internet].
DRD2, DRD3	Ananthan S, Saini SK, Zhou G, Hobrath JV, Padmalayam I, Zhai L, Bostwick JR, Antonio T, Reith ME, McDowell S, Cho E, McAleer L, Taylor M, Luedtke RR. (2014). Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity. J Med Chem 16(75):7042-60.
DRD2, DRD3	Meade JA, Free RB, Miller NR, Chun LS, Doyle TB, Moritz AE, Conroy JL, Watts VJ, Sibley DR. (2014). (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling. Psychopharmacology. 232(5):917-30.
DRD2, DRD3	Hiller C, Kling RC, Heinemann FW, Meyer K, Hubner H, Gmeiner, P. (2013). Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety. J Med Chem 56(12):5130-41.
DRD3	Chen J, Levant B, Jiang C, Keck TM, Newman AH, Wang S. (2014). Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D-epsilon receptor antagonists. J Med Chem. 57(11):4962-8.
DRD3	Furman CA, Roof RA, Moritz AE, Miller BN, Doyle TB, Free RB, Banala AK, Paul NM, Kumar V, Sibley CD, Newman AH, Sibley DR. (2014). Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. Eur Neuropsychopharmacol.
DRD3	Banala AK, Levy BA, Khatri SS, Furman CA, Roof, RA, Mishra Y, Griffin SA, Sibley DR, Luedtke RR, and Newman AH. (2011). N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. J Med Chem 54(10):3581-94.

全文献リストはこちらでもご覧いただけます　→　★